HBV Cure vignet
Meeting category
Date(s)
9 Nov 2021 - 10 Nov 2021
Meeting type
Virtual Meeting
Organizer
Silver level sponsor
Sponsor logos
Gilead logo

International Workshop on HBV Cure 2021

Related Enduring Materials

Enduring Materials
Session 1: Therapeutic Advancements for Viral Hepatitis -
Patient Selection for Clinical Trials Based on Drug Class
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
New Data From Combination Trials for Chronic Hepatitis B
Pietro Lampertico, MD, PhD
University of Milan, Italy
New Combination Therapies in Hepatitis Delta Therapy
Jeffrey S. Glenn, MD, PhD
Stanford University, United States
Session 2: Clinical Immunology and Immunotherapy Updates -
What Can We Learn by Deploying Immunological Analysis in Phase II Clinical Trials?
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
TLR-8 Agonist
Simon Fletcher, PhD
Gilead Sciences, United States
Anti-HBs Antibody
Carey Hwang, MD, PhD
Vir Biotechnology, Inc., United States
Immunotherapeutics in the Treatment of Chronic Hepatitis B
Sarah Browne, MD
Altimmune, Inc., United States
VBI-2601: Immunotherapeutic HBV Vaccine Candidate Overview
HBV Immunotherapeutic Vaccines (Lessons from HCV)
Eleanor Barnes, PhD, FRCP, F. Med. Sci.
University of Oxford, United Kingdom
A Novel Approach At Targeting the PD-1/PD-l1 Pathway: PD-l1 Lna
Anna Maria Geretti, MD, PhD, FRCPath
University of Rome, Italy / King's College London, United Kingdom
Session 3: Patient Selection, Stopping Treatment and Biomarkers -
HBsAg Loss: A Predictor of Long-Term Clinical Outcomes
Marion Peters, MD
Northwestern University, United States
Outcomes After NUC Therapy Discontinuation
Markus Cornberg, MD
Hanover Medical School; Centre for Individualised Infection Medicine, Germany
How to Handle Flares in HBV Trials With Novel Agents
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Safety Monitoring during HBV Clinical Trials and after Antiviral Discontinuation
Poonam Mishra, MD, MPH, FAASLD
US Food and Drug Administration, United States
Session 4: Update on Viral Targets for HBV/HDV Therapy -
Biological Insights Taught by Clinical Responses to Novel Hbv/Hdv Drugs
Stephan Urban, PhD
Heidelberg University Hospital, Germany
Core Inhibitors (Capsid Assembly Modulators)
Luisa Stamm, MD, PhD
Assembly Biosciences, United States
Antisense Oligos
Leigh Felton, BSc, PhD
GlaxoSmithKline, United Kingdom
STOP Agents
Matthew McClure, MD
Aligos, United States
Active Site Polymerase Inhibitor Nucleotides (APSINs)
Douglas Mayers, MD
Antios Therapeutics, United States
Update on the Efficacy and Safety of Bulevirtide for Treatment of Chronic HDV
Dmitry Manuilov, MD
Gilead Sciences, Germany
Overview
Image
HBV CURE
Welcome

Since 2014, the International Workshop on HBV Cure has been a scientific platform that acts as a catalyst to accelerate the progress for achieving a cure. Around the globe, more than 250 million people are chronically infected with hepatitis B (HBV). The purpose of the workshop was to inform the participants about the developments in the possibilities to find a cure for HBV. The meeting was highly interactive with input from experts out of the arena of basic, translational, and clinical HBV research.

The field of HBV treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available are providing great hopes for decreasing the burden of the disease, simplifying treatment, and potentially curing and eradicating HBV infection.

In order to optimize curative treatment for HBV, outstanding speakers from around the globe shared the newest therapeutic options for viral hepatitis, and experts will discuss the path forward to cure this deadly disease, leading to liver cirrhosis and liver cancer. Questions on which endpoints to use in therapeutic trials and how to combine different agents targeting the virus and/or immune system were extensively discussed.

This workshop also brought together global inter-disciplinary experts to provide a framework for how academia and industry should collaborate to achieve the goal of curing hepatitis B.

Program Chairs 2021
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
General Information
  • If you missed the previous edition of the International Workshop on HBV Cure 2020, you can watch the enduring materials. Presentations and slides are publicly available here
COVID-19 Update
Responding to the changing COVID-19 situation, the International Workshop on HBV Cure 2021 was held as a virtual workshop from 9 -10 November 2021.

We are available to answer any questions or concerns that you may have about your participation at the International Workshop on HBV Cure 2021. For more information, please contact us at federica@amededu.com.

Unique Features
- Invited lectures from international experts

- Interactive roundtable discussions

- Ample time for discussion
Who Should Attend?
- Clinicians

- Researchers

- Academia

- Industry

- Government representatives
Meeting Objectives
The objectives of this workshop are to:

- Discuss how to reach an HBV functional cure with newly developed agents targeting the immune system or the viral replication cycle;

- Develop endpoints and better biomarkers for these studies; and

- Discuss how new agents should be combined to reach the goal of a functional cure.
Learning Objectives
After attending this workshop, participants will be able to:

- Critically evaluate biomarkers used in clinical HBV studies;

- Outline advances made to cure HBV; and

- Critically assess current approaches taken to achieve the development of a functional cure.

Practical Information 

Certificate of Attendance
A certificate of attendance was sent to participants that successfully complete the program and post-meeting survey.
Language
The official language of the meeting was English.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official workshop sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Committees
Chairs 2021
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada
Organizing Committee
Harry Janssen 2019
Harry Janssen, MD, PhD
Erasmus MC, University Hospital Rotterdam, the Netherlands / Toronto Centre for Liver Disease, Canada

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Support
Silver Level Sponsor
Friend Level Sponsor

Support Our Initiative

Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in HBV Cure.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Rikke Rode via Rikke.Rode@amededu.com
 
Benefits of Support 
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgment on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level

Endorsers
Media
Welcome Message by OC Member

Marion Peters, MD (Northwestern University, United States) is pleased to invite you to join HBV Cure 2021.

This year’s workshop will shed light on new therapeutic advances for hepatitis B, criteria for patients selections, biomarkers, and new insights into clinical immunology and immunotherapy.